From July 9 to 10, 2026, the "BIOCHINA Global Forum@Korea" was held in Seoul with great success. The forum brought together key stakeholders from China, South Korea, and the global biopharmaceutical sector, including representatives from government agencies and industry associations, executives of leading pharmaceutical companies, seasoned business development and regulatory affairs experts, as well as top-tier investors specializing in the life sciences field. Together, they created a dynamic platform that bridged policy, industry, and capital. Through a diverse array of formats—including keynote speeches, high-level panel discussions, and pioneering project roadshows—the event facilitated in-depth exchanges on critical topics such as R&D trends, regulatory strategies, and commercialization pathways. These deliberations not only sparked productive dialogue but also systematically forged comprehensive cooperation channels across the entire biopharmaceutical value chain, from early-stage research to market rollout, between China and South Korea. Aaron Gu, an attorney at Han Kun Law Offices, was invited to attend the BIOCHINA Global Forum@Korea and took part in the panel discussion titled "China-Korea Collaboration Opportunities and Investment Trends," where he shared forward-looking perspectives and industry insights.
During the panel discussion, Aaron Gu engaged in in-depth exchanges with participating experts on core topics including cross-border collaboration models, Venture Capital priorities, emerging technologies such as ADC, CGT, and AI-driven drug discovery, and partnership structuring. Drawing on his extensive practical experience in the Asia-Pacific biopharmaceutical sector, Aaron Gu shared insights on cooperation opportunities and investment trends in the cross-border biopharmaceutical industry between China and South Korea, in light of industry developments. He also provided professional perspectives on the design of cross-border cooperation models and the practical considerations and key compliance issues in building commercial cooperation structures. This roundtable discussion effectively facilitated in-depth exchanges between industrial institutions in China and South Korea, helped both sides build consensus on cooperation, and uncovered new opportunities for two-way investment and collaborative development.
Following the success of BIOCHINA 2025, which welcomed 30,000 attendees, BIOCHINA continues its journey of innovation and collaborative growth. BIOCHINA focuses on frontier areas of life sciences and is committed to stepping onto the global stage, establishing an international platform that connects industry players and unites global expertise to drive collaboration.
Aaron Gu's Profile
Mr. Gu specializes in corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, Spin off-NewCo transactions, drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Specifically, Mr. Gu's services cover a full range of products including drugs, medical devices, IVDs, cosmetics, general foods, special foods, animal drugs, animal foods, etc.
